Indefinite Delivery Contract SPE2DR25D9155

The Indefinite Delivery Contract (IDC) SPE2DR25D9155 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The contract, valued at $4,999,999.00, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. The contract has an ultimate completion date of December 31, 2036 and does not have any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards.

The IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional contracts to provide worldwide pharmaceutical support to the Defense Health Agency, Department of Defense, United States Coast Guard, and other government agencies. The solicitation, expected to be issued in March 2024, will be a fully competitive, Lowest Price Technically Acceptable (LPTA) acquisition with separate awards for the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet regions, as well as a Back-Up Supplier award. The estimated total value of the PPV-G GEN V program is $30.3 billion, with the intention to have at least three different contractors to ensure the Department of Defense's resiliency and access to vital pharmaceuticals during contingencies or natural disasters.